If bulk compounding of parental or sterile products uses non-sterile chemicals, what must be documented prior to release?

• A. Extensive End Product Testing Must Be Documented Prior To Release
• B. No Testing Required
• C. Only Sterility Testing
• D. Only Chemical Analysis

Answer: (A)

When non-sterile chemicals are used to bulk-prepare parenteral or sterile products, you can’t assume the final product is safe or of consistent quality without checking everything at the end. The finished batch must undergo extensive end-product testing and that testing must be documented before release. This ensures the final product meets all quality attributes—sterility, absence of harmful pyrogens, correct potency and identity, acceptable particulates, proper packaging integrity, and appropriate appearance and labeling. The comprehensive testing addresses risks that the raw materials could introduce, providing an auditable record that the batch was evaluated against defined specifications and approved for use. Relying on only one type of testing isn’t sufficient when starting materials are non-sterile, because it wouldn’t fully verify safety and efficacy of the final product.